At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of ENDEAVOR, a randomised, open-label, phase 3 trial comparing carfilzomib plus dexamethasone versus bortezomib plus dexamethasone in patients with relapsed multiple myeloma.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement